Aceclofenac Tablet Uses: Relief From Pain and Inflammation

Aceclofenac is a non-steroidal anti-inflammatory drug (NSAID) prescribed primarily for musculoskeletal pain and inflammation. Taken as a 100 mg tablet twice daily, it is used to manage conditions like osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, dental pain, and acute low back pain. What makes aceclofenac somewhat unusual among NSAIDs is its mechanism: the drug itself is not a strong direct inhibitor of the enzymes that drive inflammation, but it converts inside the body into compounds that are, giving it an indirect profile that appears to translate into fewer gut-related side effects than some of its competitors.

How Aceclofenac Works

Most NSAIDs reduce pain and swelling by blocking cyclooxygenase enzymes, known as COX-1 and COX-2. COX-2 drives inflammation, while COX-1 has protective roles in the stomach lining. The ideal painkiller would shut down COX-2 and leave COX-1 alone. Aceclofenac gets surprisingly close to that ideal, but not through its own direct action. Research on human inflammatory cells found that aceclofenac by itself had no inhibitory effect on either COX-1 or COX-2. Instead, those cells converted aceclofenac into diclofenac and a metabolite called 4′-hydroxy diclofenac, both of which are potent COX inhibitors.¹ The 4′-hydroxy diclofenac metabolite specifically blocked COX-2 activity, which is the inflammation-driving enzyme.

This conversion happens gradually rather than all at once. A study in Clinical Pharmacology & Therapeutics concluded that aceclofenac’s ability to spare COX-1 while still inhibiting COX-2 rests on this “limited but sustained” biotransformation into diclofenac.² In practical terms, this means the drug delivers anti-inflammatory effects similar to diclofenac but with a gentler impact on the stomach, because COX-1 protective activity in the gut lining is less disrupted at any given moment.

Beyond blocking prostaglandin production, aceclofenac and its metabolites also reduce other inflammatory signaling molecules. Lab work on human cartilage cells showed that aceclofenac and 4′-hydroxy-aceclofenac significantly decreased interleukin-6 production and fully blocked prostaglandin E2 synthesis when those cells were stimulated with inflammatory triggers.³ A separate clinical study of osteoarthritis patients awaiting knee replacement surgery found that three months of aceclofenac treatment reduced prostaglandin E2 in the synovial fluid and lowered the expression of COX-2 and another inflammatory enzyme in cartilage tissue.⁴ This dual action on both prostaglandins and inflammatory cytokines helps explain why the drug performs well in joint conditions where ongoing inflammation erodes cartilage over time.

Osteoarthritis

Osteoarthritis is the condition with the deepest evidence base for aceclofenac. Multiple randomized trials lasting up to 12 weeks have compared aceclofenac 100 mg twice daily against diclofenac, naproxen, piroxicam, nabumetone, and paracetamol in adults with confirmed osteoarthritis. The drug was generally as effective as diclofenac, naproxen, and piroxicam at reducing pain and improving day-to-day function, and was more effective than paracetamol alone.⁵ Pain relief appeared as early as two weeks into treatment in some of these trials.

A meta-analysis pooling data from nine comparative studies found no statistically significant difference in pain reduction between aceclofenac and control NSAIDs, but did find a small significant advantage for aceclofenac in improving physical function.⁶ The evidence quality was graded low because of high variability between individual trials, so the function advantage should be taken cautiously. Still, what these results collectively show is that aceclofenac is a reliable performer in OA pain management, consistently matching established NSAIDs even if it does not clearly beat them on pain scores.

A four-week trial in knee osteoarthritis patients found that a controlled-release formulation of aceclofenac dropped visual analogue scale pain scores from roughly 67 mm to about 43 mm, a clinically meaningful reduction.⁷ That pattern of roughly one-third pain relief within a month is fairly typical of what NSAID therapy achieves in moderate OA.

Rheumatoid Arthritis and Ankylosing Spondylitis

In rheumatoid arthritis, aceclofenac reduces joint inflammation, pain intensity, and the duration of morning stiffness. Comparative trials have shown it to be similar in efficacy to ketoprofen, diclofenac, indomethacin, and tenoxicam in these patients. For ankylosing spondylitis, it shortens morning stiffness, reduces pain, and improves spinal mobility, with results comparable to indomethacin, naproxen, and tenoxicam.⁸

For people with these conditions, the practical upshot is that aceclofenac does not offer dramatically different pain relief compared to other prescription NSAIDs. Its main selling point in rheumatic diseases is the tolerability profile rather than superior efficacy. Morning stiffness is a particularly bothersome symptom in both rheumatoid arthritis and ankylosing spondylitis, and any NSAID that effectively shortens it can meaningfully improve quality of life. Aceclofenac accomplishes this while apparently causing less stomach trouble than some alternatives, which matters because these are chronic conditions requiring prolonged daily use.

Dental and Surgical Pain

Aceclofenac is also used for acute pain relief, particularly after dental procedures. A study of patients who had impacted wisdom teeth surgically removed found that aceclofenac 100 mg was effective for postoperative pain control, with preoperative dosing performing better than waiting until after surgery. Patients who took aceclofenac an hour before the extraction needed fewer painkiller tablets afterward and reported lower pain scores.⁹

A separate triple-blind trial compared aceclofenac 100 mg twice daily with bromelain (an enzyme derived from pineapple) for pain and swelling after lower wisdom tooth surgery. Both drugs achieved similar pain reduction by day seven, with no significant difference in the number of rescue painkillers patients required.¹⁰ For dental procedures, aceclofenac functions as a solid mid-range analgesic. If you are given a choice, the evidence on preemptive dosing is worth knowing: taking it before the procedure may get you through the first few hours with less pain than waiting until the local anesthetic wears off.

Gastrointestinal Tolerability Compared to Other NSAIDs

Stomach side effects are the Achilles’ heel of NSAIDs as a class, and they are the main reason aceclofenac was developed. The drug’s gradual, COX-1-sparing mechanism appears to give it a real edge here. A large multicenter double-blind trial comparing aceclofenac to diclofenac in knee osteoarthritis patients found that the overall incidence of predefined gastrointestinal adverse events was about 57% with aceclofenac versus roughly 74% with diclofenac. Dyspepsia specifically affected about 28% of the aceclofenac group compared to about 38% of those on diclofenac, and abdominal pain was likewise lower.¹¹ Pain relief was equivalent between the two drugs throughout the study, so the tolerability advantage did not come at the cost of effectiveness.

An Indian trial similarly found aceclofenac superior to diclofenac on measures of epigastric discomfort, dyspepsia, and abdominal pain, with better patient compliance in the aceclofenac group.¹² Another trial compared aceclofenac with piroxicam in 240 patients and found both drugs similarly effective, but reported fewer complaints of dyspepsia and epigastric pain with aceclofenac, and twice as many reports of fecal blood loss in the piroxicam group.¹³

These figures should not be interpreted to mean aceclofenac is easy on the stomach in an absolute sense. Over half of patients in the aceclofenac arm of the diclofenac comparison still experienced some gastrointestinal event. The advantage is relative, not absolute. If you have a history of stomach ulcers or GI bleeding, aceclofenac is still an NSAID and still carries risk.

Cardiovascular and Other Risks

All NSAIDs carry some cardiovascular risk, and aceclofenac is no exception. A nested case-control study examining the risk of nonfatal heart attack associated with various painkillers found that aceclofenac sat at the upper end of the range among traditional NSAIDs, with an odds ratio of about 1.59, meaning users had roughly 60% higher odds of heart attack compared to non-users. By contrast, ibuprofen’s odds ratio was 0.95, essentially no increased risk.¹⁴ This is a single observational study rather than a definitive verdict, but it is a signal worth taking seriously, especially for people already at elevated cardiovascular risk due to age, smoking, diabetes, or existing heart disease.

Postmarketing surveillance data from the United Kingdom during aceclofenac’s first year on the market compared its adverse reaction reports with those for meloxicam and rofecoxib. Aceclofenac showed lower reporting rates for gastrointestinal events and hypertension than the other two, but had higher rates of liver and kidney toxicity reports compared to meloxicam. Rofecoxib (which was later withdrawn from the market) had the highest incidence of adverse reports in nearly every category.¹⁵ Spontaneous reporting data tends to undercount side effects, so these figures describe patterns rather than true frequencies. The takeaway is that aceclofenac is not uniquely risky, but it is not uniquely safe either. The liver and renal toxicity signals mean your doctor may want to monitor liver enzymes and kidney function if you take the drug for extended periods.

Protecting the Stomach During Long-Term Use

For people who need aceclofenac regularly, adding a proton pump inhibitor (a type of acid-suppressing drug) can help reduce gut damage. An animal study found that esomeprazole significantly inhibited the gastric ulceration induced by aceclofenac, and importantly, the acid-blocker did not interfere with aceclofenac’s absorption or its conversion to diclofenac.¹⁶ This is an animal model, so the results do not translate one-to-one to humans, but co-prescribing a proton pump inhibitor with an NSAID is already standard clinical practice for patients at GI risk. The study supports that this strategy works specifically with aceclofenac and does not blunt its effectiveness.

Combination Tablets With Paracetamol

In many countries, aceclofenac is available in fixed-dose combination tablets with paracetamol (acetaminophen), and sometimes with a muscle relaxant added. These combinations are particularly popular in India and parts of Asia for managing acute flare-ups. A comparative trial in osteoarthritis patients found that the aceclofenac-paracetamol combination produced faster pain relief than aceclofenac alone during the first few hours after dosing, with the combination achieving a significantly greater sum of pain intensity difference. By the end of a ten-day treatment period, however, both groups were comparable on average pain intensity and functional improvement scores.¹⁷ In other words, the combination gets you to meaningful relief faster but does not change the end result much.

A systematic review and meta-analysis looking at paracetamol combination therapy across back pain and osteoarthritis confirmed this pattern. Adding paracetamol to aceclofenac modestly improved immediate-term pain compared to aceclofenac alone, and the combination did not increase the risk of adverse events compared to NSAID monotherapy.¹⁸

Triple-combination tablets containing aceclofenac, paracetamol, and the muscle relaxant thiocolchicoside are marketed for acute low back pain. A study of this combination found significant reductions in pain at rest, during movement, and at night after just three days, with about 70% of patients rated as having excellent pain relief by their physicians after seven days.¹⁹ None of the patients in that study discontinued therapy due to side effects. The muscle relaxant component is intended to address the spasm that often accompanies acute back pain, targeting a symptom that the NSAID-paracetamol pair does not directly treat.

How Quickly It Works and How Long It Lasts

Aceclofenac is well absorbed from the stomach and upper intestine. Peak blood levels typically arrive within one to three hours after taking a tablet, and the drug has an elimination half-life of roughly four hours.²⁰ That relatively short half-life is why the standard dosing is twice daily rather than once. It is metabolized through the liver’s cytochrome P450 enzyme system and excreted primarily through the kidneys, which is why liver and kidney function matter for dose adjustments.

Researchers have also explored formulations designed to speed up absorption. One approach using a cyclodextrin inclusion complex achieved peak blood levels in about 40 minutes rather than an hour, with a substantially higher peak concentration compared to the standard marketed tablet.²¹ These enhanced formulations are still largely experimental, but they point toward a future where a single modified tablet could deliver faster-onset relief, potentially useful for breakthrough pain episodes.

Where Aceclofenac Is and Is Not Available

One thing that trips people up is that aceclofenac is not universally available. It is approved and widely used across Europe, parts of Asia, Latin America, and the Middle East, but it is not approved in the United States.²² The U.S. market already has diclofenac (which is, after all, what aceclofenac converts into), along with a crowded field of other NSAIDs. If you encounter aceclofenac while traveling or living abroad, it occupies the same therapeutic niche that naproxen or diclofenac fills in North America. It is not a fundamentally different category of drug.

Topical Formulations

For people who want to avoid oral dosing and its systemic side effects, topical aceclofenac gels are an area of active pharmaceutical development. These are designed to deliver the drug directly to a painful joint through the skin. Gel formulations using polymers like Carbopol 934 have been developed as emulgels, achieving drug content around 90% in optimized versions.²³ The appeal is straightforward: rubbing a gel onto an arthritic knee delivers the anti-inflammatory agent locally while minimizing the amount that reaches the bloodstream, theoretically reducing both stomach and cardiovascular risks. Topical NSAIDs generally work best for superficial joints like knees and hands, where the drug does not have to penetrate deeply to reach the affected tissue. Deeper structures like the hip or spine are harder to reach through the skin.

Topical aceclofenac products are already marketed in some countries, though availability varies. They are a reasonable option for mild-to-moderate joint pain, particularly in older adults who are at higher risk of systemic side effects from oral NSAIDs. They are less likely to provide the same level of relief as a full oral dose for severe or widespread pain, but for localized osteoarthritis they represent a useful compromise between effectiveness and safety.